Protara Therapeutics (1KPA) Ratios
Protara Therapeutics Ratios
DE:1KPA's free cash flow for Q2 2026 was $-15.72M. For the 2026 fiscal year, DE:1KPA's free cash flow was decreased by $-332.00K and operating cash flow was $-15.39M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.58 | 15.71 | 11.17 | 15.01 | 21.66 |
| Quick Ratio | 14.58 | 15.71 | 11.17 | 14.81 | 21.66 |
| Cash Ratio | 4.54 | 14.85 | 6.44 | 4.20 | 8.31 |
| Solvency Ratio | -4.37 | -3.09 | -3.77 | -5.86 | -4.41 |
| Operating Cash Flow Ratio | -5.15 | -3.27 | -6.11 | -4.61 | -8.03 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 146.45M | $ 157.84M | $ 58.07M | $ 74.94M | $ 82.43M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.02 | 0.07 | 0.06 | 0.04 |
| Debt-to-Equity Ratio | 0.02 | 0.03 | 0.08 | 0.06 | 0.04 |
| Debt-to-Capital Ratio | 0.02 | 0.03 | 0.07 | 0.06 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.07 | 1.09 | 1.16 | 1.11 | 1.07 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -56.79 | -26.14 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -58.98 | -27.34 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.08 | 0.22 | 0.48 | 0.67 | 0.80 |
| Net Debt to EBITDA | 0.81 | 3.58 | 0.79 | 0.27 | 0.63 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 88.99% | 90.73% | 92.68% | 98.34% | 99.50% |
| Return on Assets (ROA) | -27.42% | -24.58% | -51.19% | -58.22% | -27.38% |
| Return on Equity (ROE) | -29.24% | -26.68% | -59.16% | -64.61% | -29.18% |
| Return on Capital Employed (ROCE) | -32.51% | -28.83% | -59.90% | -62.35% | -28.22% |
| Return on Invested Capital (ROIC) | -32.31% | -28.64% | -59.11% | -61.83% | -28.07% |
| Return on Tangible Assets | -27.81% | -25.02% | -52.98% | -58.26% | -33.03% |
| Earnings Yield | -25.16% | -41.02% | -189.74% | -218.56% | -62.32% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.10 | 0.00 | 0.14 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3496.74 | 0.00 | -2605.31 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 3496.74 | 0.00 | 2605.31 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.32 | -1.74 | -3.31 | -2.35 | -3.07 |
| Free Cash Flow Per Share | -1.32 | -1.74 | -3.32 | -2.36 | -3.12 |
| Dividend Paid and CapEx Coverage Ratio | -599.63 | -568.38 | -834.60 | -220.47 | -57.89 |
| Capital Expenditure Coverage Ratio | -599.63 | -568.38 | -834.60 | -220.47 | -57.89 |
| Operating Cash Flow Coverage Ratio | -16.78 | -7.99 | -6.87 | -4.14 | -4.77 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -24.73% | -32.99% | -176.52% | -88.07% | -46.29% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.98 | -2.43 | -0.53 | -0.46 | -1.60 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.16 | 0.65 | 0.31 | 0.30 | 0.47 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.04 | -3.03 | -0.57 | -1.14 | -2.16 |
| Price-to-Operating Cash Flow Ratio | -4.05 | -3.04 | -0.57 | -1.14 | -2.20 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | 0.06 | 0.01 | -0.01 | 0.15 |
| Enterprise Value Multiple | -3.19 | 1.12 | 0.30 | -0.19 | -1.04 |
| Enterprise Value | 182.02M | -49.58M | -12.82M | 12.43M | 47.33M |
| EV to EBITDA | -3.19 | 1.12 | 0.30 | -0.19 | -1.04 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -3.22 | 1.38 | 0.34 | -0.47 | -1.35 |
| EV to Operating Cash Flow | -3.23 | 1.38 | 0.34 | -0.47 | -1.37 |
| Tangible Book Value Per Share | 4.52 | 7.96 | 5.79 | 9.06 | 11.79 |
| Shareholders’ Equity Per Share | 4.59 | 8.12 | 6.03 | 9.07 | 14.41 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.93 | 1.02 | 1.04 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.98 | 0.80 | 0.93 | 0.40 | 0.73 |
Currency in USD
